- Rentschler Biopharma and Coriolis Pharma have formed a strategic collaboration to provide integrated services from early formulation to commercial manufacturing.
- The combined offering, available from December 2025, aims to reduce tech transfer risks and accelerate progress from development to clinical and commercial stages.
Rentschler Biopharma has entered a strategic collaboration with Coriolis Pharma to offer integrated services across the biopharmaceutical development and manufacturing process. The companies will provide clients with a unified interface and coordinated project teams to support progression from early formulation to commercial manufacturing.
The partnership aims to address increasing complexity in biopharmaceutical modalities and regulatory expectations. By aligning scientific and operational capabilities, the organisations intend to reduce tech transfer risks and streamline movement from early development to clinical and commercial stages. The collaboration reflects demand in the biologics sector for connected, science-driven services that bring together formulation expertise and contract manufacturing capabilities.
Coriolis Pharma contributes formulation and drug product development expertise, including in silico and wet lab approaches, as well as advanced analytical capabilities. The company supports projects from discovery through GMP activities and positions itself as a partner across the drug development lifecycle.
Rentschler Biopharma brings experience in bioprocess development and manufacturing for biotherapeutics, supported by a track record in reliability and quality. The company states that its focus on technical excellence, long-term partnerships and tailored solutions underpins its approach to client projects.
“This marks an important step for both our organizations and for our global clients, and their patients. Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach.”
Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma
The integrated offering will be available from December 2025 across both companies’ operations in Germany and the United States.
